JP2019524826A5 - - Google Patents

Info

Publication number

JP2019524826A5

JP2019524826A5 JP2019508247A JP2019508247A JP2019524826A5 JP 2019524826 A5 JP2019524826 A5 JP 2019524826A5 JP 2019508247 A JP2019508247 A JP 2019508247A JP 2019508247 A JP2019508247 A JP 2019508247A JP 2019524826 A5 JP2019524826 A5 JP 2019524826A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

concentration

ophthalmic pharmaceutical

pilocarpine

pharmaceutically acceptable

Prior art date

2017-08-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 52
• 239000000203 mixture Substances 0.000 claims 18
• YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 claims 14
• 229960002139 pilocarpine hydrochloride Drugs 0.000 claims 14
• RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical group Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 claims 14
• 229960001963 pilocarpine nitrate Drugs 0.000 claims 14
• 150000003839 salts Chemical class 0.000 claims 13
• QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims 11
• QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims 9
• 239000003937 drug carrier Substances 0.000 claims 9
• 229960001416 pilocarpine Drugs 0.000 claims 9
• 229920002385 Sodium hyaluronate Polymers 0.000 claims 8
• 229960001193 diclofenac sodium Drugs 0.000 claims 8
• 229940010747 sodium hyaluronate Drugs 0.000 claims 8
• YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims 8
• JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims 8
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 6
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 6
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 6
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 6
• 201000010041 presbyopia Diseases 0.000 claims 6
• 210000001519 tissue Anatomy 0.000 claims 4
• 230000004075 alteration Effects 0.000 claims 3
• 239000011521 glass Substances 0.000 claims 3
• 238000002513 implantation Methods 0.000 claims 3
• 230000000007 visual effect Effects 0.000 claims 3
• 230000002411 adverse Effects 0.000 claims 2
• 229960001259 diclofenac Drugs 0.000 claims 2
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
• 229960004752 ketorolac Drugs 0.000 claims 2
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 2
• 239000000314 lubricant Substances 0.000 claims 2
• 210000004083 nasolacrimal duct Anatomy 0.000 claims 2
• 230000004297 night vision Effects 0.000 claims 2
• 239000002674 ointment Substances 0.000 claims 2
• 238000002360 preparation method Methods 0.000 claims 2
• 230000000750 progressive effect Effects 0.000 claims 2
• 239000007921 spray Substances 0.000 claims 2
• 238000001356 surgical procedure Methods 0.000 claims 2
• 239000000725 suspension Substances 0.000 claims 2
• 238000013268 sustained release Methods 0.000 claims 2
• 239000012730 sustained-release form Substances 0.000 claims 2
• 208000002177 Cataract Diseases 0.000 claims 1
• 206010020675 Hypermetropia Diseases 0.000 claims 1
• 206010027646 Miosis Diseases 0.000 claims 1
• 208000004350 Strabismus Diseases 0.000 claims 1
• 239000003889 eye drop Substances 0.000 claims 1
• 230000004438 eyesight Effects 0.000 claims 1
• 239000000499 gel Substances 0.000 claims 1
• 201000006318 hyperopia Diseases 0.000 claims 1
• 230000004305 hyperopia Effects 0.000 claims 1
• 239000007943 implant Substances 0.000 claims 1
• 230000001939 inductive effect Effects 0.000 claims 1
• 239000003978 infusion fluid Substances 0.000 claims 1
• 230000003547 miosis Effects 0.000 claims 1
• 208000001491 myopia Diseases 0.000 claims 1
• 210000001747 pupil Anatomy 0.000 claims 1
• 239000000243 solution Substances 0.000 claims 1
• 230000000699 topical effect Effects 0.000 claims 1
• 238000002054 transplantation Methods 0.000 claims 1